Evidence map›Paper›PMID 40338421›Full record

ReviewDiscover oncology2025

The role of nanomedicine and artificial intelligence in cancer health care: individual applications and emerging integrations-a narrative review.

Prasanthi Samathoti, Rajasekhar Komarla Kumarachari, Sarad Pawar Naik Bukke, Eashwar Sai Komarla Rajasekhar, Ashish Ashokkumar Jaiswal, Zohre Eftekhari

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Prasanthi SamathotiDepartment of Pharmaceutics, MB School of Pharmaceutical Sciences (Earst While Sree Vidyanikethan College of Pharmacy), Mohan Babu University, Tirupati, 517102, Andhra Pradesh, India.
Rajasekhar Komarla KumarachariDepartment of Pharmaceutical Chemistry, Meenakshi Faculty of Pharmacy, MAHER University, Thandalam, MevalurKuppam, 602105, Tamil Nadu, India.
Sarad Pawar Naik BukkeDepartment of Pharmaceutics and Pharmaceutical Technology, Kampala International University, Western Campus, P.O. Box 71, Ishaka, Bushenyi, Uganda. drsaradpawar@kiu.ac.ug.ORCID http://orcid.org/0000-0002-5693-2953
Eashwar Sai Komarla RajasekharDepartment of Data Science and Artificial Intelligence, Indian Institute of Technology, Bhilai, Kutela Bhata, 491001, Chattisgarh, India.
Ashish Ashokkumar JaiswalUpsher-Smith Laboratories, Maple Grove, MN, 55369-6026, USA.
Zohre EftekhariDepartment of Biotechnology, Pasteur Institute of Iran, District 11, Rajabi, M9RW+M55, Tehran, Tehran Province, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains one of the deadliest diseases globally, significantly impacting patients' quality of life. Addressing the rising incidence of cancer deaths necessitates innovative approaches such as nanomedicine and artificial intelligence (AI). The convergence of nanomedicine and AI represents a transformative frontier in cancer healthcare, promising unprecedented advancements in diagnosis, treatment, and patient management. This narrative review explores the distinct applications of nanomedicine and AI in oncology, alongside their synergistic potential. Nanomedicine leverages nanoparticles for targeted drug delivery, enhancing therapeutic efficacy while minimizing adverse effects. Concurrently, AI algorithms facilitate early cancer detection, personalized treatment planning, and predictive analytics, thereby optimizing clinical outcomes. Emerging integrations of these technologies could transform cancer care by facilitating precise, personalized, and adaptive treatment strategies. This review synthesizes current research, highlights innovative individual applications, and discusses the emerging integrations of nanomedicine and AI in oncology. The goal is to provide a comprehensive understanding of how these cutting-edge technologies can collaboratively improve cancer diagnosis, treatment, and patient prognosis.

Indexed as

AI in healthcareArtificial intelligenceCancerDigital healthcareDrug deliveryNanomedicineNanoparticlesOncology

Identifiers

PMID40338421
PMCPMC12061837

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.